title: Drug treatments for schizophrenia: pragmatism in trial design shows lack of progress in drug design.
abstract: Aims. The introduction of second generation antipsychotic (SGA) medication over a decade ago led to changes in prescribing practices; these drugs have eclipsed their predecessors as treatments for schizophrenia. However, the metabolic side effects of these newer antipsychotics have been marked and there are increasing concerns as to whether these novel drugs really are superior to their predecessors in terms of the balance between risks and benefits. In this article, we review the literature regarding comparisons between first generation antipsychotic (FGA) and SGA in terms of clinical effectiveness. Methods. Large (n > 150) randomized-controlled trials (RCTs) comparing the effectiveness (efficacy and side effects) of FGA and SGA medications other than clozapine were reviewed, as were meta-analyses that included smaller studies. Results. The superiority in efficacy and reduced extrapyramidal side effects (EPSE) of SGAs is modest, especially when compared with low-dose FGAs. However, the high risk of weight gain and other metabolic disturbances associated with certain SGAs such as olanzapine is markedly higher than the risk with FGAs at the doses used in the trials. Conclusions. The efficacy profiles of various FGAs and SGAs are relatively similar, but their side effects vary between and within classes. Overall, large pragmatic trials of clinical effectiveness indicate that the care used in prescribing and managing drug treatments to ensure tolerability may be more important than the class of drug used.
authors: Department of Psychiatry, University of Cambridge, Cambridge, UK.
authors: F
authors: F
authors: Cheng
authors: P B
authors: PB
authors: Jones
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use; D015195:Drug Design; D006801:Humans; D012559:Schizophrenia
chemical_list: D014150:Antipsychotic Agents
references: Nat Med. 2007 Sep;13(9):1102-7
references: 17767166
references: Am J Psychiatry. 2006 Apr;163(4):600-10
references: 16585434
references: Soc Psychiatry Psychiatr Epidemiol. 2005 Jan;40(1):27-35
references: 15624072
references: Int J Clin Pract. 2011 Feb;65(2):189-210
references: 21129135
references: J Clin Psychiatry. 2004 Feb;65(2):267-72
references: 15003083
references: Lancet. 2008 Mar 29;371(9618):1048-9
references: 18374824
references: Br J Psychiatry. 1999 Sep;175:217-23
references: 10645321
references: BMJ. 2000 Dec 2;321(7273):1371-6
references: 11099280
references: Am J Psychiatry. 2008 Nov;165(11):1420-31
references: 18794207
references: J Clin Psychiatry. 2001 Mar;62(3):179-84
references: 11305704
references: N Engl J Med. 2005 Sep 22;353(12):1209-23
references: 16172203
references: Am J Psychiatry. 2005 May;162(5):947-53
references: 15863797
references: JAMA. 2003 Sep 24;290(12):1624-32
references: 14506122
references: Am J Psychiatry. 2007 Jul;164(7):1050-60
references: 17606657
references: BMJ. 1997 Jun 14;314(7096):1764
references: 9202525
references: J Clin Psychiatry. 2011;72 Suppl 1:19-23
references: 22217439
references: Am J Psychiatry. 1999 Apr;156(4):544-9
references: 10200732
references: Lancet. 2008 Mar 29;371(9618):1085-97
references: 18374841
references: Lancet. 2003 May 10;361(9369):1581-9
references: 12747876
references: Lancet. 2009 Jan 3;373(9657):31-41
references: 19058842
references: Br J Psychiatry. 1997 Dec;171:502-8
references: 9519087
references: Arch Gen Psychiatry. 2003 Jun;60(6):553-64
references: 12796218
references: Schizophr Bull. 2006 Oct;32(4):715-23
references: 16540702
references: Postgrad Med J. 2005 Apr;81(954):203
references: 15811880
references: Am J Psychiatry. 2004 Aug;161(8):1334-49
references: 15285957
references: Can J Psychiatry. 1999 Mar;44(2):164-7
references: 10097837
references: Psychiatry Clin Neurosci. 2009 Feb;63(1):17-22
references: 19067997
references: Pharmacopsychiatry. 2010 Jun;43(4):138-46
references: 20205074
references: BMJ. 2007 Jan 6;334 Suppl 1:s7
references: 17204765
references: J Am Acad Child Adolesc Psychiatry. 2001 Jul;40(7 Suppl):4S-23S
references: 11434484
references: Schizophr Res. 1999 Jan 4;35(1):51-68
references: 9988841
references: J Clin Psychopharmacol. 2011 Dec;31(6):698-704
references: 22020356
references: Arch Gen Psychiatry. 1993 May;50(5):369-76
references: 8098203
references: Arch Gen Psychiatry. 2006 Oct;63(10):1079-87
references: 17015810
references: BMJ. 2008 Nov 11;337:a2390
references: 19001484
references: Clin Ther. 2012 May;34(5):1023-40
references: 22494521
references: Arch Gen Psychiatry. 1988 Sep;45(9):789-96
references: 3046553
references: Lancet. 2009 Aug 22;374(9690):620-7
references: 19595447
references: Br J Psychiatry. 2012 May;200(5):387-92
references: 22442101